Review

Comparative Analysis of Liposomal and Surfactant-Based Drug Delivery Systems

Sengar Ashutosh *

Posted Date: 6 November 2025

doi: 10.20944/preprints202511.0347.v1

Keywords: liposomal drug delivery; surfactant-based systems; nanocarriers; targeted therapeutics; drug resistance

 doi:10.20944/preprints202511.0347.v1

Review

Comparative Analysis of Liposomal and Surfactant-Based Drug Delivery Systems

Sengar Ashutosh

Dept. of Pharmaceutics, College of Pharmacy, S.R. Group of Institutions, Gwalior Road, Ambabai, Jhansi, U.P.; ashutoshsengar26567@gmail.com

Abstract

The pharmaceutics world today is rapidly transforming with the evolution of next-generation drug delivery systems. The current article discusses the history, mechanism of action, application, and limitations of liposomal and surfactant-based drug delivery systems. Liposomes have evolved from simple bilayer vesicles to advanced PEGylated nanocarriers that are common today in wide use for site-specific chemotherapeutic and biologic delivery. Surfactant-based products such as micelles and emulsions increase drug solubility and bioavailability and bring definitive benefits to drug resistance management. The review gives a critical appraisal of FDA-approved pharmaceuticals like Doxil®, illustrated with clinical effectiveness and regulatory impact. Challenges in immune responses, stability, and scalability issues are well-explored with focus on keeping commercialization as a concern. Comparative views postulate complementary strengths of surfactant carriers and liposomes in which the former possesses ease in formulation and facilitation of permeability and the latter possesses targeting and biocompatibility advantage. Based on integration of 25 key primary source pieces of information, the article provides birds-eye view of current capability and constraint, and direction in the future as hybrid delivery systems and novel nanocarrier design. The aim of this article is to raise awareness among researchers, clinicians, and regulators of translational and therapeutic potential of such systems and highlight the necessity of interdisciplinary solutions towards bridging contemporary constraints to clinical take-up.

Keywords: liposomal drug delivery; surfactant-based systems**;** nanocarriers; targeted therapeutics**;** drug resistance

1. Introduction to Advanced Drug Delivery Technologies

Drug delivery systems of the present era have been transformed by the increasing need for precision, controlled release, and increased bioavailability. Such systems are created to deliver therapeutic agents at the right time, in the right amount, and to the right place of action, with little systemic side effects and maximum compliance by the patient [1].

Nanocarrier systems such as liposomes, polymeric nanoparticles, and micelles are efficient drug delivery systems to deliver drugs in a targeted fashion. These can encapsulate hydrophilic and hydrophobic drugs and also get surface modified, thus being extremely versatile and efficient in crossing biological barriers [2].

Liposome preparations, in particular, have been greatly acclaimed since they are biocompatible, decrease drug toxicity, and possess improved pharmacokinetics. Vesicular systems facilitate the delivery of drugs to tissues or cells of interest, especially in malignancy and infections [3].

Meanwhile, oral drug delivery technologies, such as chewable tablets and mouth-dissolving films, are improving pediatric and geriatric drug delivery. These technologies are convenient without compromising pharmacological efficacy [4].

Present design methodologies integrate physicochemical characterization, stability profiling, and in vitro/in vivo correlation to render drug delivery systems in line with regulatory and

 doi:10.20944/preprints202511.0347.v1

therapeutic specifications. Success of innovation in new delivery technologies is reliant on scientific discipline [5].

Promising as they are, liposomal drug delivery systems do have their shortfalls, like stability concerns, complexity in manufacture, and scaling up [2]. Such deficiencies are nonetheless being overcome daily due to new advancements in lipid structure, surface science, and encapsulation technologies [6].

2. Evolution and Mechanisms of Liposomal Drug Delivery

The evolution of drug delivery through liposomes began with the discovery of liposomes as bilayer lipid vesicles to deliver hydrophilic and lipophilic drugs. They have a membrane-mimicking nature, so very good carriers for systemic delivery [7].

With passage of time, tuning of particle size, functionalization of surfaces, and adjustment in lipid composition have improved liposome efficacy by a significant degree. PEGylation, for instance, extends circulation time through avoidance of opsonization and phagocytosis by the mononuclear phagocyte system [8].

Liposomal formulations act by three fundamental mechanisms: trapping drug inside aqueous core or lipid bilayer, ligand binding or passive entry (e.g., enhanced permeability and retention effect), and temperature- or pH-dependent controlled release [9].

Some of these vesicles possess characteristic pharmacokinetic features. Their ability to prolong systemic circulation and particularly to build up in diseased tissues promotes therapeutic activity and reduces off-target toxicity [10].

In addition, “stealth” liposomes, composed of hydrophilic polymers like polyethylene glycol (PEG), have shown improved biodistribution and lowered immune cell recognition, leading to extended-release patterns [11].

Recent developments have also improved targeting modalities, including the use of antibodies, peptides, or aptamers, which permit active targeting to specific cell receptors, improving site-specific drug delivery [12].

Table 1. Evolution and Mechanisms of Liposomal Drug Delivery.

Aspect	Details	Reference
Initial Discovery	- Liposomes identified as bilayer vesicles - Capable of encapsulating hydrophilic and lipophilic drugs - Structure mimics biological membranes	[7]
Advancements in Composition	- Optimization of lipid types and particle size - Surface functionalization for improved delivery efficiency	[8]
PEGylation (Stealth Technology)	- PEG coating prevents immune recognition (opsonization) - Prolongs circulation time	[8,11]
Mechanisms of Action	1. **Encapsulation**: Drugs held in aqueous core or lipid bilayer 2. **Targeting**: Ligands or EPR effect for passive/active accumulation 3. **Controlled Release**: Triggered by pH or temperature	[9]
Pharmacokinetic Benefits	- Extended systemic circulation - Site-specific accumulation in pathological tissues - Reduced off-target toxicity	[10]
Advanced Targeting Strategies	- Use of antibodies, peptides, aptamers for receptor-specific delivery - Enhances precision medicine potential	[12]

3. Surfactant-Based Drug Delivery and Its Role in Drug Resistance

Surfactant drug delivery systems utilize amphiphilic molecules to enhance drug permeability, solubility, and bioavailability of water-insoluble drugs. These systems, i.e., micelles, emulsions, and niosomes, are extremely flexible and easy to formulate [13].

 doi:10.20944/preprints202511.0347.v1

Surfactants permit drugs to extend at the molecular level to enhance their penetration across biological membranes to a great extent. This is especially useful in oral andando pulmonary drug delivery, where dissolution rate and solubility are significant rate-controlling factors [14].

Surfactant carriers have been promising in oncology to reverse multidrug resistance (MDR) in cancer chemotherapy. Through the inhibition of efflux pumps like P-glycoprotein or altering membrane fluidity, these systems will increase intracellular drug concentration and therapeutic effect [15].

Compared to traditional formulation, drug biodistribution can be altered and pharmacokinetic performance optimized by surfactant-mediated carriers, leading to greater therapeutic effect spanning longer times with reduced toxicity [16].

Surfactant-based systems, as opposed to liposomal systems, are spontaneously self-assembled and drug loading more. Liposomes are targetable as well as biocompatibility more and hence both systems are complementary depending on the therapeutic scenario [17].

While easy to use, there are issues in the shape of possible surfactant toxicity with high-dose therapy and stability issues. Additional research intends to customize surfactactin concentration, composition, and type to minimize such issues at the cost of no loss of effectiveness [18].

4. Clinical Applications and FDA-Approved Liposomal Formulations

Liposomal drug delivery systems have transitioned from research tools to therapeutically proven treatments. Liposomal formulations are FDA-approved for several indications as they have the ability to enhance therapeutic indices and reduce systemic toxicity [19].

One of the most notable examples is Doxil®, which is the first FDA-approved formulation of liposomal doxorubicin. Liposomal PEGylation enhances its circulation half-life and reduces cardiotoxicity, with the best efficacy in ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma [20].

Stealth liposomes are now the focus of clinical translation, most notably in cytotoxic chemotherapy delivery in cancer therapy. Polyethylene glycol (PEG) surface modification allows for immune evasion, with extended systemic residence and improved tumor accumulation [21].

In the clinic, liposomes have been used not just in oncology but also for antifungal, antimicrobial, and vaccine use. Their pharmacokinetic advantages, such as reduced clearance and site-specific delivery, are some of the main drivers of their regulatory approval [22].

Regardless of this, challenges to the commercialization of liposomal drugs persist. These are the mass production complexity, high cost of production, instability issues, and strict regulatory demands for characterization and quality control [23].

5. Challenges in Liposomal and Surfactant-Based Drug Delivery Systems

Though they show clinical potential, liposomal and surfactant delivery systems are still constrained by stability and toxicity issues. Liposomes, for example, tend to aggregate, oxidize, and degrade drugs over time, affecting shelf-life and therapeutic action [24].

Another issue is immunogenicity. PEGylated liposomes, despite being formulated to avoid immune recognition, induce accelerated blood clearance (ABC) following repeated dosing, decreasing their effectiveness in chronic treatment [25].

On the manufacturing front, surfactant as well as liposomal systems are multi-step operations involving lamellarity control, surface type control, and particle size control. Technically as well as financially still problematic with regard to reproducibility from batch-to-batch when being scaled-up [1].

Also necessary with controlling so intricate of a product are ultra-characterizations of release profiles, encapsulation rates, sterility, and physicochemical attributes—still an additional step appended to development and regulatory approval [2].

 doi:10.20944/preprints202511.0347.v1

Against all these challenges, scientists are devising new lipids formulations, stimulus-sensitive nanocarriers, and liposomes or hybrid polymer-ligand delivery systems for enhanced targetability and stability. Automation-based continuous manufacturing systems are also under discussion for streamline production efficiently [3].

Conclusion

Emergent drug carrier systems like surfactant-based and liposomal systems have revolutionized therapy with site-specific delivery of drugs, improved bioavailability, and diminished systemic toxicity. From rudimentary lipid vesicles to PEGylated stealth liposomes, liposome technologies have significantly broadened their clinical applications. Surfactant-based systems, however, have set record-breaking records in solving solubility and resistance issues with drugs, particularly anticancer therapy.

FDA-approved liposomal drugs such as Doxil® are indications of the translational success of nanocarriers but with issues of instability, immunogenicity, and scale-up remaining. They highlight the issues of innovation in manufacturing capability, formulation science, and regulation policy.

Comparative studies have shown that while liposomes are a leader in biocompatibility and target-specific delivery, surfactant-based systems are a leader in formulation flexibility and membrane interaction. The future of advanced drug delivery is hybrid technology, whereby the two strategies are merged to leverage gaps in therapy.

Liposomal and surfactant-based systems thus represent an emerging and dynamic field of pharmaceutical science of vast potential in targeted therapy, chronic disease management, and future therapies.

References

1. Sengar, A. (2025). Advancements in liposomal drug delivery and nanocarrier systems for targeted therapeutics. Preprints. https://doi.org/10.20944/preprints202503.1603.v1
2. Sengar, A. (2025). Liposomal formulations in clinical use: Progress, challenges, and future directions. Preprints. https://doi.org/10.20944/preprints202503.1663.v1
3. Sengar, A. (2025). The role of liposomal drug delivery in modern medicine and the expanding potential of nanocarriers. Preprints. https://doi.org/10.20944/preprints202503.1802.v1
4. Sengar, A. (2025). Chewable tablets and mouth-dissolving films: Revolutionizing drug administration. Preprints. https://doi.org/10.20944/preprints202503.1852.v1
5. Sengar, A. (2025). Formulation and evaluation techniques in novel drug delivery systems. Preprints. https://doi.org/10.20944/preprints202503.1953.v1
6. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
7. Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9(2), 12. https://doi.org/10.3390/pharmaceutics9020012
8. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome-assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
9. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
10. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
11. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
12. Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015). New developments in liposomal drug delivery. Chemical Reviews, 115(19), 10938–10966. https://doi.org/10.1021/acs.chemrev.5b00046

 doi:10.20944/preprints202511.0347.v1

13. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102
14. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123–140. https://doi.org/10.1016/S0378-5173(97)00135-X
15. Kaur, P., Garg, T., Rath, G., Murthy, R. S., & Goyal, A. K. (2014). Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Discovery Today, 19(2), 243–249. https://doi.org/10.1016/j.drudis.2013.09.002
16. Allen, T. M. (1994). Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in Pharmacological Sciences, 15(7), 215–220. https://doi.org/10.1016/0165-6147(94)90314-X
17. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
18. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
19. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
20. Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9(2), 12. https://doi.org/10.3390/pharmaceutics9020012
21. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome-assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
22. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
23. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
24. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery. International Journal of Pharmaceutics, 154(2), 123–140. https://doi.org/10.1016/S0378-5173(97)00135-X
25. Barenholz, Y. (2012). Doxil®—Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020